SIRP-α binding proteins and methods of use thereof

Patent metadata

Field	Value
Publication number	US-12084499-B2
Application number	US-202318162879-A
Country	US
Kind code	B2
Filing date	Feb 1, 2023
Priority date	Sep 27, 2018
Publication date	Sep 10, 2024
Grant date	Sep 10, 2024

Abstract

Provided herein are compositions, methods and uses involving antibodies that specifically bind to signal regulatory protein-α (SIRPα) and modulate the activity of SIRPα.

First claim

What is claimed:

1. A method of treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of an antibody or antigen binding fragment thereof that binds to human SIRPα, wherein the antibody or antigen binding fragment thereof comprises:
(a) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having the amino acid sequence of SEQ ID NO:67; and
(b) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having the amino acid sequence of SEQ ID NO:80.

2. The method of claim 1 , wherein the antibody or the antigen-binding fragment thereof comprises:
(a) a VL comprising: a VL CDR1 comprising the amino acid sequence of SEQ ID NO:62, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:63, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:65; and
(b) a VH comprising: a VH CDR1 comprising the amino acid sequence of SEQ ID NO:78, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:69, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:57.

3. The method of claim 1 , wherein the antibody or the antigen-binding fragment thereof comprises a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:67.

4. The method of claim 1 , wherein the antibody or the antigen-binding fragment thereof comprises a VL comprising the amino acid sequence of SEQ ID NO:67.

5. The method of claim 1 , wherein the antibody or the antigen-binding fragment thereof comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:80.

6. The method of claim 1 , wherein the antibody or the antigen-binding fragment thereof comprises a VH comprising the amino acid sequence of SEQ ID NO:80.

7. The method of claim 1 , wherein the antibody or the antigen-binding fragment thereof comprises a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:67; and a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:80.

8. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises a VL comprising the amino acid sequence of SEQ ID NO:67; and a VH comprising the amino acid sequence of SEQ ID NO:80.

9. The method of claim 1 , wherein the antibody or the antigen-binding fragment thereof comprises a light chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:143.

10. The method of claim 1 , wherein the antibody or the antigen-binding fragment thereof comprises a light chain comprising the amino acid sequence of SEQ ID NO:143.

11. The method of claim 1 , wherein the antibody or the antigen-binding fragment thereof comprises a heavy chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:119.

12. The method of claim 1 , wherein the antibody or the antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:119.

13. The method of claim 1 , wherein the antibody or the antigen-binding fragment thereof comprises a light chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:143, and a heavy chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:119.

14. The method of claim 1 , wherein the antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO:143, and a heavy chain comprising the amino acid sequence of SEQ ID NO:119.

15. The method of claim 1 , wherein the antigen-binding fragment is a Fab, Fab′, (Fab′) 2 , Fv, or scFv fragment.

16. The method of claim 1 , wherein the antibody or the antigen-binding fragment thereof comprises a human IgG1 Fc region or a mutant thereof.

17. The method of claim 1 , wherein the antibody or the antigen-binding fragment thereof comprises a heavy chain Fc region comprising the amino acid sequence selected from the group consisting of SEQ ID NOS: 144 and 155-159.

18. The method of claim 1 , wherein the antibody or the antigen-binding fragment thereof further comprises a light chain constant region comprising the amino acid sequence of SEQ ID NO:211.

19. The method of claim 1 , wherein the antibody or the antigen-binding fragment thereof comprises: a light chain constant region comprising the amino acid sequence of SEQ ID NO:211; and a heavy chain Fc region comprising the amino acid sequence selected from the group consisting of SEQ ID NOS:144 and 155-159.

20. The method of claim 1 , wherein the antibody is a monoclonal antibody.

21. The method of claim 1 , wherein the antibody is a humanized, human, or chimeric antibody.

22. The method of claim 1 , wherein the antibody or the antigen-binding fragment thereof is conjugated to an agent.

23. The method of claim 22 , wherein the agent is selected from the group consisting of a radioisotope, a metal chelator, an enzyme, a fluorescent compound, a bioluminescent compound, and a chemiluminescent compound.

24. The method of claim 1 , wherein the cancer is a cancer selected from the group consisting of colorectal cancer, head and neck squamous cell carcinoma, acute myeloid leukemia, diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma and mantle cell lymphoma.

25. The method of claim 1 , wherein the cancer is non-Hodgkin's lymphoma.

26. The method of claim 1 , wherein the cancer is a cancer selected from the group consisting of Grade 1 follicular lymphoma, Grade 2 follicular lymphoma, Grade 3a follicular lymphoma, Grade 3b follicular lymphoma, relapsed follicular lymphoma, refractory follicular lymphoma, relapsed DLBCL, and refractory DLBCL.

27. The method of claim 1 , wherein the cancer cells express SIRPα.

28. The method of claim 27 , wherein the SIRPα is one or more of 6 SIRPα haplotypes:
(a) wherein the 6 SIRPα haplotypes consist of SIRPα v1, SIRPα v2, SIRPα v3, SIRPα v4, SIRPα v5, and SIRPα v6, and
(b) wherein SIRPα v1 comprising SEQ ID NO: 149 in the IgV-domain, SIRPα v2 comprising SEQ ID NO:150 in the IgV-domain, SIRPα v3 comprising SEQ ID NO:151 in the IgV-domain, SIRPα v4 comprising SEQ ID NO:152 in the IgV-domain, SIRPα v5 comprising SEQ ID NO: 153 in the IgV-domain, and SIRPα v6 comprising SEQ ID NO: 154 in the IgV-domain.

29. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof is co-administered with a second therapeutic agent.

30. The method of claim 29 , wherein the second therapeutic agent is selected from the group consisting of cetuximab and rituximab.

31. The method of claim 1 , wherein the subject is selected from the group consisting of a human and a monkey.

Assignees

• Celgene Corp

Inventors

• Abbasian Mahan
• Chan Henry H
• Escoubet Laure
• Fenalti Gustavo
• Hariharan Kandasamy
• Leung Monica Wai Ling
• Mavrommatis Konstantinos
• Mikolon David P
• Raymon Heather K
• Santos Carlo Steven
• Sun Jeonghoon
• Trout Christina Valerie

Classifications

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/732

  Antibody-dependent cellular cytotoxicity [ADCC] · CPC title

• C07K2317/567

  Framework region [FR] · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/34

  Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title